 and inspection of the 
PMA clinical and nonclinical information and improve the coordination 
of a preapproval inspection between the applicant and FDA.

II. Significance of Guidance

    This draft guidance is being issued consistent with FDA's good 
guidance practices regulation (21 CFR 10.115). The draft guidance, when 
finalized will represent the agency's current thinking on ``The Review 
and Inspection of Premarket Approval Applications under the Bioresearch 
Monitoring Program.'' It does n